These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 15462695)

  • 41. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
    Bobrie G;
    Clin Ther; 2012 Aug; 34(8):1720-34.e3. PubMed ID: 22853847
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
    N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Long-term follow-up of cardiovascular risk markers in patients with hypertension. Rationale, design, and baseline characteristics of the i-Search Plus Registry].
    Tebbe U; Lüders S; de Haan F; Bramlage P; Böhm M; Thoenes M; Paar WD; Schrader J;
    Med Klin (Munich); 2007 Oct; 102(10):824-32. PubMed ID: 17928966
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The risks and benefits of initial irbesartan/hydrochlorothiazide combination therapy in patients with severe hypertension.
    Lapuerta P; Franklin S
    J Clin Hypertens (Greenwich); 2009 May; 11(5):277-83. PubMed ID: 19534037
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study).
    Leidig M; Bambauer R; Kirchertz EJ; Szabã T; Handrock R; Leinung D; Baier M; Schmieder RE
    Clin Nephrol; 2008 Jun; 69(6):425-32. PubMed ID: 18538118
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
    Weisser B; Gerwe M; Braun M; Funken C
    Arzneimittelforschung; 2005; 55(9):505-13. PubMed ID: 16229114
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension.
    Pool JL; Guthrie RM; Littlejohn TW; Raskin P; Shephard AM; Weber MA; Weir MR; Wilson TW; Wright J; Kassler-Taub KB; Reeves RA
    Am J Hypertens; 1998 Apr; 11(4 Pt 1):462-70. PubMed ID: 9607385
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Arterial hypertension in obese patients. Rationale for a prospective medical care study in the family doctor's practice].
    Bramlage P; Sharma AM; Kirch W
    MMW Fortschr Med; 2004 Aug; 146 Suppl 2():45-50. PubMed ID: 16739358
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
    Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
    Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Short-term effects of irbesartan treatment on microalbuminuria in patients with normotensive type 2 diabetes.
    Cetinkalp SS; Karadeniz MM; Erdogan MA; Ozgen GA; Yilmaz CO
    Saudi Med J; 2008 Oct; 29(10):1414-8. PubMed ID: 18946564
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.
    Neutel JM; Germino FW; Smith D
    J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):84-9. PubMed ID: 16470487
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial.
    Berl T; Hunsicker LG; Lewis JB; Pfeffer MA; Porush JG; Rouleau JL; Drury PL; Esmatjes E; Hricik D; Pohl M; Raz I; Vanhille P; Wiegmann TB; Wolfe BM; Locatelli F; Goldhaber SZ; Lewis EJ;
    J Am Soc Nephrol; 2005 Jul; 16(7):2170-9. PubMed ID: 15930097
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
    Berl T; Hunsicker LG; Lewis JB; Pfeffer MA; Porush JG; Rouleau JL; Drury PL; Esmatjes E; Hricik D; Parikh CR; Raz I; Vanhille P; Wiegmann TB; Wolfe BM; Locatelli F; Goldhaber SZ; Lewis EJ;
    Ann Intern Med; 2003 Apr; 138(7):542-9. PubMed ID: 12667024
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension.
    Kochar M; Guthrie R; Triscari J; Kassler-Taub K; Reeves RA
    Am J Hypertens; 1999 Aug; 12(8 Pt 1):797-805. PubMed ID: 10480473
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria.
    Persson F; Rossing P; Reinhard H; Juhl T; Stehouwer CD; Schalkwijk C; Danser AH; Boomsma F; Frandsen E; Parving HH
    Diabetes Care; 2009 Oct; 32(10):1873-9. PubMed ID: 19587362
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical study of western medicine combined with Chinese medicine based on syndrome differentiation in the patients with polarized hypertension.
    Chen SL; Liu XY; Xu WM; Mei WY; Chen XL
    Chin J Integr Med; 2012 Oct; 18(10):746-51. PubMed ID: 22965699
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reasons for not intensifying antihypertensive treatment (RIAT): a primary care antihypertensive intervention study.
    Ferrari P; Hess L; Pechere-Bertschi A; Muggli F; Burnier M
    J Hypertens; 2004 Jun; 22(6):1221-9. PubMed ID: 15167458
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Comparison of the antihypertensive activity of fosinopril and irbesartan].
    Angulo E; Robles NR; Grois J; Barquero A; Pérez Miranda M
    An Med Interna; 2002 Nov; 19(11):571-5. PubMed ID: 12522893
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of the antihypertensive efficacy of irbesartan/HCTZ and valsartan/HCTZ combination therapy: impact of age and gender.
    Asmar R; Oparil S
    Clin Exp Hypertens; 2010; 32(8):499-503. PubMed ID: 21091220
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension.
    Derosa G; Cicero AF; Gaddi A; Mugellini A; Ciccarelli L; Fogari R
    J Cardiovasc Pharmacol; 2005 Jun; 45(6):599-604. PubMed ID: 15897788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.